<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01490450</url>
  </required_header>
  <id_info>
    <org_study_id>IM133-004</org_study_id>
    <secondary_id>2011-004016-29</secondary_id>
    <nct_id>NCT01490450</nct_id>
  </id_info>
  <brief_title>Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy</brief_title>
  <official_title>A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging, Multi-Center Study to Evaluate the Efficacy and Safety of BMS-945429 Subcutaneous Injection in Adults With Active Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSL Behring</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize the safety, efficacy and dose response of&#xD;
      BMS-945429 in subjects with active Psoriatic Arthritis and an inadequate response to&#xD;
      Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-biologic Disease modifying&#xD;
      anti-rheumatic drugs (DMARDs).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20)</measure>
    <time_frame>At 16 weeks</time_frame>
    <description>The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response Rate</measure>
    <time_frame>Week 16 and Week 24</time_frame>
    <description>To calculate the PASI score, the psoriasis plaques found on each body region are graded for their combined redness, thickness, and scaliness. The severity of the plaques in each region is graded on a 0 to 4 scale, with 0 meaning no involvement and 4 meaning severe involvement. Next, the amount of surface area on each body region that is covered by the plaques is calculated. The total surface area affected by psoriasis is graded from 0 to 6, with 0 meaning no involvement and 6 meaning greater than 90 percent of the region covered in plaques.&#xD;
These grades are then fed into an equation to determine the patient's PASI score. The PASI score then is used as a clinical assessment of the patient's psoriasis involvement. A person free of psoriasis has a score of 0 and the score could be as high as 72.&#xD;
PASI 75 means that the person's PASI score dropped by 75 percent as a result of the psoriasis treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Achieving ACR50 and ACR70 Response Rate</measure>
    <time_frame>Week 16 and Week 24</time_frame>
    <description>The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Achieving ACR20 Response Rate at Week 24</measure>
    <time_frame>Week 24</time_frame>
    <description>The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Achieving a Health Assessment Questionnaire (HAQ) Response</measure>
    <time_frame>Weeks 16 and Week 24</time_frame>
    <description>For each item, there is a four-level difficulty scale that is scored from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). There are 20 questions in eight categories of functioning - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The highest component score in each category determines the score for the category, unless aids or devices are required. Dependence on equipment or physical assistance increases a lower score to the level of 2 to more accurately represent underlying disability. The eight category scores are averaged into an overall HAQ score on a scale from zero (no disability) to three (completely disabled). The scale is not truly continuous but has 25 possible values (i.e., 0, 0.125, 0.250, 0.375 â€¦ 3).&#xD;
Response is measured by a reduction of at least 0.3 unit from baseline in HAQ index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline at Week 16 in Short Form (36) [SF-36] Scores</measure>
    <time_frame>Baseline and Week 16</time_frame>
    <description>The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline at Week 24 in SF-36 Scores</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Anti-clazakizumab Antibodies</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Arthritis, Psoriatic</condition>
  <arm_group>
    <arm_group_label>PBO: Placebo matching BMS-945429</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-945429 (25mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-945429 (100mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BMS-945429 (200mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo matching BMS-945429</intervention_name>
    <description>Injection, Subcutaneous, 0 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label</description>
    <arm_group_label>PBO: Placebo matching BMS-945429</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-945429</intervention_name>
    <description>Injection, Subcutaneous, 25 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label</description>
    <arm_group_label>BMS-945429 (25mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-945429</intervention_name>
    <description>Injection, Subcutaneous, 100 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label</description>
    <arm_group_label>BMS-945429 (100mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BMS-945429</intervention_name>
    <description>Injection, Subcutaneous, 200 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label</description>
    <arm_group_label>BMS-945429 (200mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be on a stable background Methotrexate (MTX) therapy prior to Day1/Randomization.&#xD;
             Subjects must have taken MTX for at least 3 months at a dose â‰¥ 15 mg/week to a maximum&#xD;
             weekly dose of â‰¤ 25 mg/week, and be at a stable dose for 4 weeks prior to&#xD;
             randomization (Day 1). Methotrexate dose â‰¥ 15 mg/week that was not efficacious and&#xD;
             that was decreased due to toxicity as low as 10 mg/week is allowed&#xD;
&#xD;
          -  Inadequate response to NSAID and/or non-biologic DMARD&#xD;
&#xD;
          -  Minimum of 3 swollen and 3 tender joints&#xD;
&#xD;
          -  Active psoriatic skin lesions over minimum 3% body surface area&#xD;
&#xD;
          -  high sensitivity C-reactive protein (hsCRP) â‰¥ 0.3 mg/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previously received or currently receiving concomitant biologic therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Diego Arthritis Medical Clinic</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Arthritis Clinic</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Research Associates, Llc</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Arthritis Research Center</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Associates Of Mississippi</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Box Arthritis And Rheumatology Of The Carolinas, Pllc</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research Of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Penn Rheumatology Associates, P.C.</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1015</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1428</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tucuman</city>
        <zip>4000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cairns</city>
        <state>Queensland</state>
        <zip>4870</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Maroochydore</city>
        <state>Queensland</state>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Woodville</city>
        <state>South Australia</state>
        <zip>5011</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shenton Park</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manitoba Clinic</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre De Rhumatologie De L Est Du Quebec</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <zip>G5L 8W1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre De Recherche Musculo-Squelettique</name>
      <address>
        <city>Trois-rivieres</city>
        <state>Quebec</state>
        <zip>G8Z 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Praha 2</city>
        <zip>128 50</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Planegg</city>
        <zip>82152</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Debrecen</city>
        <zip>4012</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mexico</city>
        <state>Aguascalientes</state>
        <zip>20127</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45190</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dabrowka</city>
        <zip>62-069</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Poznan</city>
        <zip>60773</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>01-868</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0083</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0084</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Durban</city>
        <state>KWA ZULU Natal</state>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Panorama, Cape Town</city>
        <state>Western CAPE</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pinelands, Cape Town</city>
        <state>Western Cape</state>
        <zip>7405</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>France</country>
  </removed_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 14, 2011</study_first_submitted>
  <study_first_submitted_qc>December 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2011</study_first_posted>
  <results_first_submitted>October 7, 2021</results_first_submitted>
  <results_first_submitted_qc>October 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2021</results_first_posted>
  <disposition_first_submitted>July 24, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 24, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 13, 2015</disposition_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Subcutaneous, every 4 weeks for 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Clazakizumab (25mg)</title>
          <description>Subcutaneous, 25 mg, every 4 weeks, for 24 weeks</description>
        </group>
        <group group_id="P3">
          <title>Clazakizumab (100mg)</title>
          <description>Subcutaneous, 100 mg, every 4 weeks, for 24 weeks</description>
        </group>
        <group group_id="P4">
          <title>Clazakizumab (200mg)</title>
          <description>Subcutaneous, 200 mg, every 4 weeks, for 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Request to discontinue treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No longer met study criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Subcutaneous, every 4 weeks for 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Clazakizumab (25mg)</title>
          <description>Subcutaneous, 25 mg, every 4 weeks, for 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Clazakizumab (100mg)</title>
          <description>Subcutaneous, 100 mg, every 4 weeks, for 24 weeks</description>
        </group>
        <group group_id="B4">
          <title>Clazakizumab (200mg)</title>
          <description>Subcutaneous, 200 mg, every 4 weeks, for 24 weeks</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="41"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="41"/>
            <count group_id="B5" value="165"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.0" spread="10.53"/>
                    <measurement group_id="B2" value="49.8" spread="14.05"/>
                    <measurement group_id="B3" value="49.3" spread="10.84"/>
                    <measurement group_id="B4" value="44.7" spread="13.75"/>
                    <measurement group_id="B5" value="47.9" spread="12.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20)</title>
        <description>The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
        <time_frame>At 16 weeks</time_frame>
        <population>Modified Intent-to-Treat (MITT) defined as all randomized subjects that received at least one dose of the study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous, every 4 weeks for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clazakizumab (25mg)</title>
            <description>Subcutaneous, 25 mg, every 4 weeks, for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Clazakizumab (100mg)</title>
            <description>Subcutaneous, 100 mg, every 4 weeks, for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>Clazakizumab (200mg)</title>
            <description>Subcutaneous, 200 mg, every 4 weeks, for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Achieving American College of Rheumatology Criteria 20% Response Rate (ACR20)</title>
          <description>The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
          <population>Modified Intent-to-Treat (MITT) defined as all randomized subjects that received at least one dose of the study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.3"/>
                    <measurement group_id="O2" value="46.3"/>
                    <measurement group_id="O3" value="52.4"/>
                    <measurement group_id="O4" value="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response Rate</title>
        <description>To calculate the PASI score, the psoriasis plaques found on each body region are graded for their combined redness, thickness, and scaliness. The severity of the plaques in each region is graded on a 0 to 4 scale, with 0 meaning no involvement and 4 meaning severe involvement. Next, the amount of surface area on each body region that is covered by the plaques is calculated. The total surface area affected by psoriasis is graded from 0 to 6, with 0 meaning no involvement and 6 meaning greater than 90 percent of the region covered in plaques.&#xD;
These grades are then fed into an equation to determine the patient's PASI score. The PASI score then is used as a clinical assessment of the patient's psoriasis involvement. A person free of psoriasis has a score of 0 and the score could be as high as 72.&#xD;
PASI 75 means that the person's PASI score dropped by 75 percent as a result of the psoriasis treatment.</description>
        <time_frame>Week 16 and Week 24</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous, every 4 weeks for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clazakizumab (25mg)</title>
            <description>Subcutaneous, 25 mg, every 4 weeks, for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Clazakizumab (100mg)</title>
            <description>Subcutaneous, 100 mg, every 4 weeks, for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>Clazakizumab (200mg)</title>
            <description>Subcutaneous, 200 mg, every 4 weeks, for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response Rate</title>
          <description>To calculate the PASI score, the psoriasis plaques found on each body region are graded for their combined redness, thickness, and scaliness. The severity of the plaques in each region is graded on a 0 to 4 scale, with 0 meaning no involvement and 4 meaning severe involvement. Next, the amount of surface area on each body region that is covered by the plaques is calculated. The total surface area affected by psoriasis is graded from 0 to 6, with 0 meaning no involvement and 6 meaning greater than 90 percent of the region covered in plaques.&#xD;
These grades are then fed into an equation to determine the patient's PASI score. The PASI score then is used as a clinical assessment of the patient's psoriasis involvement. A person free of psoriasis has a score of 0 and the score could be as high as 72.&#xD;
PASI 75 means that the person's PASI score dropped by 75 percent as a result of the psoriasis treatment.</description>
          <population>MITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6"/>
                    <measurement group_id="O2" value="12.2"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2"/>
                    <measurement group_id="O2" value="19.5"/>
                    <measurement group_id="O3" value="28.6"/>
                    <measurement group_id="O4" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Achieving ACR50 and ACR70 Response Rate</title>
        <description>The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
        <time_frame>Week 16 and Week 24</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous, every 4 weeks for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clazakizumab (25mg)</title>
            <description>Subcutaneous, 25 mg, every 4 weeks, for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Clazakizumab (100mg)</title>
            <description>Subcutaneous, 100 mg, every 4 weeks, for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>Clazakizumab (200mg)</title>
            <description>Subcutaneous, 200 mg, every 4 weeks, for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Achieving ACR50 and ACR70 Response Rate</title>
          <description>The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
          <population>MITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ACR50 (16 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3"/>
                    <measurement group_id="O2" value="29.3"/>
                    <measurement group_id="O3" value="35.7"/>
                    <measurement group_id="O4" value="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR50 (24 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6"/>
                    <measurement group_id="O2" value="34.1"/>
                    <measurement group_id="O3" value="35.7"/>
                    <measurement group_id="O4" value="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 (16 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4"/>
                    <measurement group_id="O2" value="17.1"/>
                    <measurement group_id="O3" value="14.3"/>
                    <measurement group_id="O4" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ACR70 (24 weeks)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="19.5"/>
                    <measurement group_id="O3" value="23.8"/>
                    <measurement group_id="O4" value="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Achieving ACR20 Response Rate at Week 24</title>
        <description>The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
        <time_frame>Week 24</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous, every 4 weeks for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clazakizumab (25mg)</title>
            <description>Subcutaneous, 25 mg, every 4 weeks, for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Clazakizumab (100mg)</title>
            <description>Subcutaneous, 100 mg, every 4 weeks, for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>Clazakizumab (200mg)</title>
            <description>Subcutaneous, 200 mg, every 4 weeks, for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Achieving ACR20 Response Rate at Week 24</title>
          <description>The ACR20/50/70 is a composite measure defined as both improvement of 20%, 50% or 70% in the number of tender and number of swollen joints, and a 20%, 50% or 70% improvement in three of the following five criteria: patient global assessment, physician global assessment, functional ability measure [most often Health Assessment Questionnaire (HAQ)], visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP).</description>
          <population>MITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1"/>
                    <measurement group_id="O2" value="56.1"/>
                    <measurement group_id="O3" value="57.1"/>
                    <measurement group_id="O4" value="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Achieving a Health Assessment Questionnaire (HAQ) Response</title>
        <description>For each item, there is a four-level difficulty scale that is scored from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). There are 20 questions in eight categories of functioning - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The highest component score in each category determines the score for the category, unless aids or devices are required. Dependence on equipment or physical assistance increases a lower score to the level of 2 to more accurately represent underlying disability. The eight category scores are averaged into an overall HAQ score on a scale from zero (no disability) to three (completely disabled). The scale is not truly continuous but has 25 possible values (i.e., 0, 0.125, 0.250, 0.375 â€¦ 3).&#xD;
Response is measured by a reduction of at least 0.3 unit from baseline in HAQ index.</description>
        <time_frame>Weeks 16 and Week 24</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous, every 4 weeks for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clazakizumab (25mg)</title>
            <description>Subcutaneous, 25 mg, every 4 weeks, for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Clazakizumab (100mg)</title>
            <description>Subcutaneous, 100 mg, every 4 weeks, for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>Clazakizumab (200mg)</title>
            <description>Subcutaneous, 200 mg, every 4 weeks, for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Achieving a Health Assessment Questionnaire (HAQ) Response</title>
          <description>For each item, there is a four-level difficulty scale that is scored from 0 to 3, representing normal (no difficulty) (0), some difficulty (1), much difficulty (2), and unable to do (3). There are 20 questions in eight categories of functioning - dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The highest component score in each category determines the score for the category, unless aids or devices are required. Dependence on equipment or physical assistance increases a lower score to the level of 2 to more accurately represent underlying disability. The eight category scores are averaged into an overall HAQ score on a scale from zero (no disability) to three (completely disabled). The scale is not truly continuous but has 25 possible values (i.e., 0, 0.125, 0.250, 0.375 â€¦ 3).&#xD;
Response is measured by a reduction of at least 0.3 unit from baseline in HAQ index.</description>
          <population>MITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6"/>
                    <measurement group_id="O2" value="48.8"/>
                    <measurement group_id="O3" value="45.2"/>
                    <measurement group_id="O4" value="39.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.8"/>
                    <measurement group_id="O2" value="51.2"/>
                    <measurement group_id="O3" value="47.6"/>
                    <measurement group_id="O4" value="36.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline at Week 16 in Short Form (36) [SF-36] Scores</title>
        <description>The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.</description>
        <time_frame>Baseline and Week 16</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous, every 4 weeks for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clazakizumab (25mg)</title>
            <description>Subcutaneous, 25 mg, every 4 weeks, for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Clazakizumab (100mg)</title>
            <description>Subcutaneous, 100 mg, every 4 weeks, for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>Clazakizumab (200mg)</title>
            <description>Subcutaneous, 200 mg, every 4 weeks, for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline at Week 16 in Short Form (36) [SF-36] Scores</title>
          <description>The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.</description>
          <population>MITT</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mental component</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.507"/>
                    <measurement group_id="O2" value="1.2" spread="1.502"/>
                    <measurement group_id="O3" value="3.7" spread="1.478"/>
                    <measurement group_id="O4" value="1.1" spread="1.516"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical component</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.236"/>
                    <measurement group_id="O2" value="6.5" spread="1.236"/>
                    <measurement group_id="O3" value="4.6" spread="1.217"/>
                    <measurement group_id="O4" value="4.1" spread="1.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline at Week 24 in SF-36 Scores</title>
        <description>The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Subcutaneous, every 4 weeks for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clazakizumab (25mg)</title>
            <description>Subcutaneous, 25 mg, every 4 weeks, for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Clazakizumab (100mg)</title>
            <description>Subcutaneous, 100 mg, every 4 weeks, for 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>Clazakizumab (200mg)</title>
            <description>Subcutaneous, 200 mg, every 4 weeks, for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline at Week 24 in SF-36 Scores</title>
          <description>The SF-36 questionnaire consists of eight scales yielding two summary measures: physical and mental health. The physical health measure includes four scales of physical functioning (10 items), role-physical (4 items), bodily pain (2 items), and general health (5 items). The mental health measure is composed of vitality (4 items), social functioning (2 items), role-emotional (3 items), and mental health (5 items). To score the SF-36, scales are standardized with a scoring algorithm to obtain a score ranging from 0 to 100. Higher scores indicate better health status.</description>
          <population>MITT</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="38"/>
                <count group_id="O3" value="36"/>
                <count group_id="O4" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mental component</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.646"/>
                    <measurement group_id="O2" value="1.4" spread="1.538"/>
                    <measurement group_id="O3" value="3.9" spread="1.548"/>
                    <measurement group_id="O4" value="2.1" spread="1.689"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical component</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="1.420"/>
                    <measurement group_id="O2" value="8.2" spread="1.360"/>
                    <measurement group_id="O3" value="5.7" spread="1.363"/>
                    <measurement group_id="O4" value="6.4" spread="1.461"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Anti-clazakizumab Antibodies</title>
        <time_frame>Up to 24 weeks</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>Clazakizumab (25mg)</title>
            <description>Subcutaneous, 25 mg, every 4 weeks, for 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Clazakizumab (100mg)</title>
            <description>Subcutaneous, 100 mg, every 4 weeks, for 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Clazakizumab (200mg)</title>
            <description>Subcutaneous, 200 mg, every 4 weeks, for 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anti-clazakizumab Antibodies</title>
          <population>MITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="42"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 24 weeks per participant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Subcutaneous, every 4 weeks for 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Clazakizumab (25mg)</title>
          <description>Subcutaneous, 25 mg, every 4 weeks, for 24 weeks</description>
        </group>
        <group group_id="E3">
          <title>Clazakizumab (100mg)</title>
          <description>Subcutaneous, 100 mg, every 4 weeks, for 24 weeks</description>
        </group>
        <group group_id="E4">
          <title>Clazakizumab (200mg)</title>
          <description>Subcutaneous, 200 mg, every 4 weeks, for 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Adute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>CSL Behring</organization>
      <phone>610-878-4000</phone>
      <email>clinicaltrials@cslbehring.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

